SCHEMBL1177334

SCHEMBL1177334

CC1(C)C/C(=N/O)c2sc(Br)nc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.45
HSD17B10 Q99714 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX15 P16050 1/20 0.41
ALDH1A1 P00352 11/20 0.39
LMNA P02545 2/20 0.36
GAA P10253 1/20 0.36
ATAD2 Q6PL18 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
TSHR P16473 2/20 0.34
PIK3CD O00329 2/20 0.33
PIK3CA P42336 2/20 0.33
PIK3CB P42338 2/20 0.33
PIK3CG P48736 2/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
MAPK1 P28482 1/20 0.32
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177338 1.00 HTT (0.45) HTTHSD17B10SMN1; SMN2ALOX15ALDH1A1
SCHEMBL1177336 1.00 HTT (0.45) HTTHSD17B10SMN1; SMN2ALOX15ALDH1A1
SCHEMBL304836 0.74 ALDH1A1 (0.69) HTTHSD17B10SMN1; SMN2ALDH1A1NPC1
SCHEMBL11910042 0.62 ALDH1A1 (0.36) HTTHSD17B10SMN1; SMN2ALOX15ALDH1A1
SCHEMBL13393784 0.61 HSD17B10 (0.34) HTTHSD17B10SMN1; SMN2ALOX15ALDH1A1
SCHEMBL12680949 0.56 ALDH1A1 (0.69) HTTHSD17B10SMN1; SMN2ALDH1A1ATAD2
SCHEMBL305618 0.56 ALDH1A1 (1.00) HTTHSD17B10SMN1; SMN2ALDH1A1ATAD2
Bromide SCHEMBL3828169 0.55 ALDH1A1 (0.96) HTTHSD17B10SMN1; SMN2ALDH1A1ATAD2
SCHEMBL19782906 0.55 GRM5 (0.35) ALDH1A1
SCHEMBL13562182 0.54 HSD17B10 (0.37) HTTHSD17B10SMN1; SMN2ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881827-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-09-28 EP disclosed
US-7888344-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2011-02-15 US disclosed
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306060-A1 Fused Thiazole Derivatives as Kinase Inhibitors MAP4K2, PDPK1, DAPK2 HTT 1259/4885HSD17B10 2934/4885SMN1; SMN2 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.